Dr. Lal Path Labs Ltd. — PPTs, 30-01-2025: Investor Presentation

**Q3 FY25 Performance Overview**

Dr. Lal PathLabs has recorded a robust growth trajectory, with revenue reaching ₹597 crore in Q3 FY25, a year-on-year increase of 10.7%. Year-to-date revenue stands at ₹1,859 crore, growing 10.6% compared to the previous year. The operational efficiency has shown improvement, leading to an EBITDA of ₹154 crore (9.6% growth) and a profit after tax (PAT) of ₹98 crore, reflecting a 19.3% increase. The company has successfully expanded its footprint, particularly in Western India, where it saw a 15% revenue contribution in Q3.

The strategic focus on deeper market penetration, enhanced digital infrastructure, and optimized business model has resulted in significant operational leverage. Sample volumes increased by 10.3%, with patient growth at 3.8%. Additionally, positive momentum continues in Suburban Diagnostics, contributing to overall growth. Investors should note the company's commitment to innovation and infrastructure expansion as it continues solidifying its position in the diagnostics industry.